Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells
Melisa Ruiz-Gutierrez, Özge Vargel Bölükbaşı, Gabriela Alexe, Adriana G. Kotini, Kaitlyn Ballotti, Cailin E. Joyce, David W. Russell, Kimberly Stegmaier, Kasiani Myers, Carl D. Novina, Eirini P. Papapetrou, Akiko Shimamura
Melisa Ruiz-Gutierrez, Özge Vargel Bölükbaşı, Gabriela Alexe, Adriana G. Kotini, Kaitlyn Ballotti, Cailin E. Joyce, David W. Russell, Kimberly Stegmaier, Kasiani Myers, Carl D. Novina, Eirini P. Papapetrou, Akiko Shimamura
View: Text | PDF
Research Article Hematology Therapeutics

Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells

  • Text
  • PDF
Abstract

Monosomy 7 and deletion of 7q, known as del(7q), are common clonal cytogenetic abnormalities associated with high-grade myelodysplastic syndrome (MDS) arising in inherited and acquired bone marrow failure. Current nontransplant approaches to treat marrow failure may be complicated by stimulation of clonal outgrowth. To study the biological consequences of del(7q) within the context of a failing marrow, we generated induced pluripotent stem cells (iPSCs) derived from patients with Shwachman-Diamond syndrome (SDS), a bone marrow failure disorder with MDS predisposition, and genomically engineered a 7q deletion. The TGF-β pathway was the top differentially regulated pathway in transcriptomic analysis of SDS versus SDSdel(7q) iPSCs. SMAD2 phosphorylation was increased in SDS relative to wild-type cells, consistent with hyperactivation of the TGF-β pathway in SDS. Phospho-SMAD2 levels were reduced following 7q deletion in SDS cells and increased upon restoration of 7q diploidy. Inhibition of the TGF-β pathway rescued hematopoiesis in SDS iPSCs and in bone marrow hematopoietic cells from SDS patients while it had no impact on the SDSdel(7q) cells. These results identified a potential targetable vulnerability to improve hematopoiesis in an MDS predisposition syndrome and highlighted the importance of the germline context of somatic alterations to inform precision medicine approaches to therapy.

Authors

Melisa Ruiz-Gutierrez, Özge Vargel Bölükbaşı, Gabriela Alexe, Adriana G. Kotini, Kaitlyn Ballotti, Cailin E. Joyce, David W. Russell, Kimberly Stegmaier, Kasiani Myers, Carl D. Novina, Eirini P. Papapetrou, Akiko Shimamura

×

Figure 4

The TGF-β pathway is upregulated in SDS iPSCs and modulated following 7q deletion.

Options: View larger image (or click on image) Download as PowerPoint
The TGF-β pathway is upregulated in SDS iPSCs and modulated following 7q...
(A) Representative images of phospho-SMAD2 immunofluorescence (green) in normal, SDS1, SDSdel(7q), and SDSdel(7q)+7 iPSCs. Nuclei are stained with DAPI (blue). Scale bar: 10 μm. (B) Mean signal intensity for nuclear phospho-SMAD2 signal was quantified in individual cells (n = 100 cells/line/experiment) of normal (1157), SDS1 (SDS1.5), SDSdel(7q) (SDS1.5D5Cre4.9#9), and SDSdel(7q)+7 (SDS1.5D5Cre4.9+7#2) iPSCs. (C) Relative methylcellulose hematopoietic colony formation per 10,000 cells plated for normal or SDS primary marrow mononuclear cells following lentiviral transduction of the indicated shRNA: scrambled (c), SMAD3 shRNA 1 (sh1), and SMAD3 shRNA2 (sh2). Cells were plated in triplicate for each of 3 independent experiments (n = 3). (D) Representative images of myeloid (top) and erythroid (bottom) colonies from normal or SDS primary marrow with scrambled (c) versus SMAD3 shRNA (sh1). Scale bar: 1 mm. (E) Hematopoietic colony formation per 15,000 iPSC-derived cells plated in methylcellulose for normal (blue, N2.12 D1-1, n = 3), SDS (orange, SDS1.5, n = 3), and SDSdel(7q) (green, SDS1.5D5Cre4.9#9, n = 3) iPSCs in the presence or absence of 1 μM SD208. Mean ± SD are shown for myeloid (top) and erythroid (bottom) colonies. (F) CD33 expression at day 7 of myeloid differentiation showing means ± SD for normal (blue, N2.12 D1-1, n = 4) and SDS (orange, SDS1.5, n = 4) iPSCs. *P < 0.05 by unpaired, 2-tailed Student’s t test (B, C, E, and F).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts